NLG
PHAS

New Legacy Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

New Legacy Group’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-240,575
Closed -$144K – 28
2022
Q2 		$144K Hold
240,575
– – 0.29% 28
2022
Q1 		$318K Hold
240,575
– – 0.12% 24
2021
Q4 		$628K Buy
+240,575
New +$727K 0.12% 16

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PTP
Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

New Legacy Group's PHAS Position: Q3 2022 in Review

New Legacy Group sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 240,575 shares — an estimated $144K sold.

New Legacy Group first reported a position in PHAS in Q4 2021 and held it in 3 quarters. The position peaked at $628K in Q4 2021. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

  • New Legacy Group reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • New Legacy Group sold 240,575 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $144K.
  • New Legacy Group first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • New Legacy Group's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $628K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on New Legacy Group's 13F filing for Q3 2022, filed 14 Nov 2022.